DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2013年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/2635

Title: Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness.
Authors: Yada, Koji
Nogami, Keiji
Ogiwara, Kenichi
Shima, Midori
Keywords: activation analysis;
blood coagulation;
factor IX, factor VII, factor X – prothrombin drug combination
factor VIII – human
hemophilia A
inhibitors
Issue Date: 15-May-2013
Publisher: Blackwell Pub.
Citation: Journal of thrombosis and haemostasis Vol.11 No.5 p.902-910
Abstract: BACKGROUND AND OBJECTIVES: Activated prothrombin complex concentrates (APCCs), utilized in bypassing therapy for hemophiliacs with inhibitor, contain factors (Fs) VII, FII, FIX and FX, and their active forms. A recent report has demonstrated that mixtures of APCC and FVIII potentiated thrombin generation, in vitro, in plasma from patients with severe hemophilia A, but the mechanism(s) involved remains unknown. RESULTS: APCC (0.05 U mL(-1) ) increased FVIII activity ~ 4-fold within 1 min in one-stage clotting assays, followed by a return to initial levels within 10 min. This reaction was dependent on the presence of tissue factor and phospholipid. Thrombin generation produced from APCC was ~ 3.5-fold greater in the presence of FVIII than that in its absence. SDS-PAGE analysis revealed that APCC sequentially proteolyzed the heavy chain of FVIII at Arg(372) and Arg(740) , followed by cleavage at Arg(336) . Proteolysis was prevented by FVIIa inhibitor, but not by hirudin, supporting the concept that APCC itself possessed the potential to activate FVIII in early coagulation phases, and that FVIIa in APCC contributed mainly to this reaction. APCC-mediated FVIII activation was unaffected by the addition of anti-FVIII inhibitor antibodies, irrespective of epitope specificity. Anti-C2 type 1 inhibitors, however, diminished the inactivation phase of the APCC reaction by inhibiting cleavage at Arg(336) . CONCLUSION: Small amounts of APCC, relative to the standard concentration used for clinical purposes, could activate FVIII directly, even in the presence of anti-FVIII antibodies. Combination therapy based on mixtures of APCC and FVIII could have significant beneficial implications for the treatment of hemophilia A patients with inhibitors.
Description: 博士(医学)・甲第601号・平成25年7月22日
発行元の猶予期間終了の後、本文を登録予定(2014.05)
URI: http://hdl.handle.net/10564/2635
ISSN: 15387933
Academic Degrees and number: 24601A601
Degree-granting date: 2013-07-22
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2013年度

Files in This Item:

File Description SizeFormat
01本文の要旨.pdf本文の要旨243.43 kBAdobe PDFView/Open
02審査要旨.pdf審査要旨252.89 kBAdobe PDFView/Open
03本文.pdf本文3.21 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback